Duke University Medical Center is conducting a research study to see if the experimental study drug, ASP3291, is safe and effective at controlling ulcerative colitis without causing significant side effects.

Eligibility Criteria
To participate in this study, you must be an adult between the ages of 18-65 who meets the following criteria:
• Has active ulcerative colitis
• Has screening laboratory values, test, and physical exam within acceptable ranges

Duration
Your participation could last for approximately 14 weeks and will include about seven clinic visits and one follow-up phone call.


Copernicus Group IRB: CAT1-12-189; Duke eIRB: Pro00038948

For more information, contact Tameka Street at 919-684-0190.